“The forces and the law of nature always have the final say on the well being of the earth. It is only the human force which influences the maximum on nature as it is the most “”intellectual”” in terms of the existing living being on the earth. Human beings dominate the ecological balance of nature in a major way without any serious “”Intelligent”” competition.
Scaling the Health care Industry market forces on an identical platform, which are definitely more dynamic than nature, the same is driven by majority of identified and unidentified forces. The”” identified”” /””captured”” forces drive the market in such a way which work towards the creation of scenario dominated by the Policies, Regulators and the policy makers in a major way. Below is an event Dashboard for the week starting on the 15th June 2009 and the events and news which have taken place in the whole week. Policies are driving the market to an extent of 25% of the market Dashboard followed by the Global & Indian Pharma drug trends to an extent of another 25%. Competition and generic drugs occupy the show with another 24 % in totality.
Policies being the most “”intellectual”” part of the dashboard drivers would be the major driving force of the industry. The economic policies for the drugs, their manufacture, their sale and presence in the market is due to a “”set”” policy framework which on a broader level is sequenced and guided by the governments of the countries where the drugs are manufactured. It is the trends of the recessed times to move towards cost effective drug products and all companies of the drug industry are moving in that direction in their own ways and adopted methods. The most cost effective drugs are the off patent drugs/generics/ copy cat versions of branded drugs. Policy drivers in all major countries of the world whether developed or developing are focused towards manufacturing, promoting, selling and consuming generics in a major way. Adhering to the policies formulated by the regulatory agencies of the respective countries is becoming the major objective of the drug industry today. In case the same does not happen in an effective manner, the regulators or the policy makers move towards enforcement of the same in their own way by declarations (as press releases) or website announcements or notices to the concerned.
The drug companies which sell generic products can do so by conducting Bio-equivalence studies with reference to the branded drug. For the same they outsource the studies to CRO’s of their choice which conducts bio-equivalence studies.
Veeda Clinical Research is an Indian CRO with extensive experience in conducting Bio-equivalence studies. ”